Evidence map›Paper›PMID 32610439›Full record

ArticleMolecules (Basel, Switzerland)2020

Poly-arginine-18 (R18) Confers Neuroprotection through Glutamate Receptor Modulation, Intracellular Calcium Reduction, and Preservation of Mitochondrial Function.

Gabriella MacDougall, Ryan S Anderton, Amy Trimble, Frank L Mastaglia, Neville W Knuckey, Bruno P Meloni

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gabriella MacDougallPerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.ORCID 0000-0002-6432-4675
Ryan S AndertonPerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Amy TrimblePerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Frank L MastagliaPerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Neville W KnuckeyPerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.
Bruno P MeloniPerron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.ORCID 0000-0003-0964-0648
The University of Western Australia · AUPerron Institute for Neurological and Translational Science · AU

Funding

University Postgraduate Award (UPA) from the University of Notre Dame, Australia. N/A
6 · The paper itself

Abstract

Recent studies have highlighted that a novel class of neuroprotective peptide, known as cationic arginine-rich peptides (CARPs), have intrinsic neuroprotective properties and are particularly effective anti-excitotoxic agents. As such, the present study investigated the mechanisms underlying the anti-excitotoxic properties of CARPs, using poly-arginine-18 (R18; 18-mer of arginine) as a representative peptide. Cortical neuronal cultures subjected to glutamic acid excitotoxicity were used to assess the effects of R18 on ionotropic glutamate receptor (iGluR)-mediated intracellular calcium influx, and its ability to reduce neuronal injury from raised intracellular calcium levels after inhibition of endoplasmic reticulum calcium uptake by thapsigargin. The results indicate that R18 significantly reduces calcium influx by suppressing iGluR overactivation, and results in preservation of mitochondrial membrane potential (ΔΨm) and ATP production, and reduced ROS generation. R18 also protected cortical neurons against thapsigargin-induced neurotoxicity, which indicates that the peptide helps maintain neuronal survival when intracellular calcium levels are elevated. Taken together, these findings provide important insight into the mechanisms of action of R18, supporting its potential application as a neuroprotective therapeutic for acute and chronic neurological disorders.

Indexed as

AnimalsCalciumCells, CulturedCell SurvivalCerebral CortexEndoplasmic ReticulumGlutamic AcidHumansMitochondriaNeuronsNeuroprotectionNeuroprotective AgentsPeptidesRatsReceptors, GlutamateCalciumGlutamic AcidNeuroprotective AgentsPeptidespolyarginineReceptors, Glutamatecationic arginine-rich peptides (CARPs)ionotropic glutamate receptorsmitochondrial membrane potential (ΔΨm)neuroprotectionpoly-arginine-18 (R18)ROS

Identifiers

PMID32610439
PMCPMC7412265
OpenAlexW3037063882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.